Search Within

Parisa Momtaz

Formats
  1. Journal Article (27)
  2. Meeting Abstract (22)
  3. Book Section (4)
  4. Research Letter (1)
Groups
  1. Department of Medicine (54)
  2. Melanoma Disease Management Team (54)
  3. Melanoma and Immunotherapeutics Service (54)
  4. Solid Tumor Oncology Division (54)
  5. Survivorship Research (54)
  6. Weinberg Fellows (54)

More Groups

People
  1. Michael Postow (36)
  2. Alexander Shoushtari (32)
  3. Paul Chapman (31)
  4. Jedd Wolchok (29)
  5. Margaret Callahan (29)
  6. Katherine Panageas (25)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (5)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (6)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Pocket Oncology (4)
  3. Clinical Cancer Research (3)
  4. Nature (3)
  5. JAMA Oncology (2)
  6. Oncotarget (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Oxford University Press (4)
  3. Wolters Kluwer Health | Lippincott Williams & Wilkins (4)
  4. American Association for Cancer Research (3)
  5. Nature Publishing Group (3)
  6. Wiley Blackwell (3)

More Publishers

Results (54)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)
    Meeting Abstract

    Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies
    Journal Article

    Momtaz, P.; Pentsova, E.; Abdel-Wahab, O.; Diamond, E.; Hyman, D.; Merghoub, T.; You, D.; Gasmi, B.; Viale, A.; Chapman, P. B.
    Oncotarget (2016)

    Fulltext@MSK | Save
  • Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis
    Journal Article

    Kuk, D.; Shoushtari, A. N.; Barker, C. A.; Panageas, K. S.; Munhoz, R. R.; Momtaz, P.; Ariyan, C. E.; Brady, M. S.; Coit, D. G.; Bogatch, K.; more...
    The Oncologist (2016)

    Fulltext@MSK | Save
  • Reply to A. Indini et al.
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab over 30 minutes
    Journal Article

    Momtaz, P.; Park, V.; Panageas, K. S.; Postow, M. A.; Callahan, M.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab (ipi) over 30 minutes (min)
    Meeting Abstract

    Momtaz, P.; Park, V.; Panageas, K.; Guillen, J. D.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Patterns of long-term survival following Ipilimumab (Ipi): The Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
    Meeting Abstract

    Page, D. B.; Naidoo, J.; Momtaz, P.; Bogatch, K.; Kuk, D.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Postow, M.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save
  • Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAF(V600E)mutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi)
    Meeting Abstract

    Momtaz, P.; Gaskell, A. A.; Merghoub, T.; Viale, A.; Chapman, P. B.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway
    Journal Article

    Momtaz, P.; Postow, M. A.
    Pharmacogenomics and Personalized Medicine (2014)

    Fulltext@MSK | Save